Founded in 2015 in Spokane, Washington by Dan Roark and Jon Copeland, Gestalt Diagnostics builds enterprise digital pathology software for hospitals, reference labs, and research organizations. Its PathFlow and PathCloud platforms digitize and manage whole-slide pathology images and integrate clinically validated AI applications directly into the diagnostic workflow, helping pathologists detect and characterize cancer faster and more consistently. The company also offers healthcare IT services including LIS migration, data integration, and staff augmentation, positioning itself as both a pathology platform and a lab-modernization partner. Gestalt's AI-based platform has been adopted for clinical use by large U.S. labs. In 2025 the company raised a $7.5M Series A led by Cowles Ventures, with TVF Funds, Inland Imaging Investments, KickStart Funds, and Pacific Northwest angels participating, to expand its AI tools for cancer detection.